Dynamic contrast-enhanced magnetic resonance imaging of the metastatic potential of melanoma xenografts

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):e121-7. doi: 10.1016/j.ijrobp.2011.12.019. Epub 2012 Feb 28.

Abstract

Purpose: Gadolinium diethylene-triamine penta-acetic acid (Gd-DTPA)-based dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has been suggested as a useful noninvasive method for characterizing the physiologic microenvironment of tumors. In the present study, we investigated whether Gd-DTPA-based DCE-MRI has the potential to provide biomarkers for hypoxia-associated metastatic dissemination.

Methods and materials: C-10 and D-12 melanoma xenografts were used as experimental tumor models. Pimonidazole was used as a hypoxia marker. A total of 60 tumors were imaged, and parametric images of K(trans) (volume transfer constant of Gd-DTPA) and v(e) (fractional distribution volume of Gd-DTPA) were produced by pharmacokinetic analysis of the DCE-MRI series. The host mice were killed immediately after DCE-MRI, and the primary tumor and the lungs were resected and prepared for histologic assessment of the fraction of pimonidazole-positive hypoxic tissue and the presence of lung metastases, respectively.

Results: Metastases were found in 11 of 26 mice with C-10 tumors and 14 of 34 mice with D-12 tumors. The primary tumors of the metastatic-positive mice had a greater fraction of hypoxic tissue (p = 0.00031, C-10; p < 0.00001, D-12), a lower median K(trans) (p = 0.0011, C-10; p < 0.00001, D-12), and a lower median v(e) (p = 0.014, C-10; p = 0.016, D-12) than the primary tumors of the metastatic-negative mice.

Conclusions: These findings support the clinical attempts to establish DCE-MRI as a method for providing biomarkers for tumor aggressiveness and suggests that primary tumors characterized by low K(trans) and low v(e) values could have a high probability of hypoxia-associated metastatic spread.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers, Tumor* / analysis
  • Biomarkers, Tumor* / pharmacokinetics
  • Cell Hypoxia / physiology*
  • Contrast Media* / pharmacokinetics
  • Female
  • Gadolinium DTPA* / pharmacokinetics
  • Humans
  • Lung
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / secondary*
  • Magnetic Resonance Imaging / methods*
  • Melanoma, Experimental / metabolism
  • Melanoma, Experimental / physiopathology
  • Melanoma, Experimental / secondary*
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Neoplasm Transplantation
  • Nitroimidazoles* / analysis
  • Nitroimidazoles* / pharmacokinetics
  • Transplantation, Heterologous
  • Tumor Microenvironment / physiology

Substances

  • Biomarkers, Tumor
  • Contrast Media
  • Nitroimidazoles
  • pimonidazole
  • Gadolinium DTPA